Assoicate Profressor Furic is Head of Translational Prostate Cancer Research at the PeterMac. In this role, A/Prof Furic is responsible for a portfolio of basic and translational studies in collaboration with researchers and clinicians.

Associate Profressor Furic is a basic and translational research scientist. His current research focuses on oncogenic signalling in prostate cancer, especially signaling impacting protein synthesis, and the identification and validation of novel therapeutic targets, including the development and testing of novel theranostic ligands.

Associate Professor Furic has made key discoveries in understanding the reprogramming of protein synthesis as a vulnerability in prostate cancer (Clin Can Res 2016, Eur Urol 2018). The overarching goal of his research program is to identify and target molecular pathways which are activated in all prostate cancer cells to address the challenge of tumour heterogeneity. His research has recently identified tRNA epitranscriptomic modifications as a vulnerability in prostate cancer (EMBO 2019). His laboratory uses biochemical and molecular biology approaches to gain a better understanding of the molecular mechanisms responsible for prostate cancer progression. He has significant experience in developing and working with genetically engineered mouse models (GEMM) and patient-derived xenografts (PDX) of prostate cancer for pre-clinical drug testing (Mol Can Ther 2021, Nat Comm 2021).

Assocaite Professor Furic’s research is supported by competitive grant funding from NHMRC, US Department of Defense, VCA, US Prostate Cancer Foundation (US PCF), other national and international philanthropic organisations and commercial contracts.

Associate Professor Furic is an Investigator of the Prostate Theranostics (ProsTIC) Centre at the PeterMac.